As our understanding of the pathogenesis of cancers grows and new treatment modalities become available, so too does the number of key research questions in oncology that need answering. Frontiers in Oncology
is working with members of our Editorial Board to tackle some of these key questions through Editor’s Challenges, each of which pose a key question in the oncology field.
We are delighted to present this Editor’s Challenge, led by Dr. Abhishek Mahajan, asking how precision oncology can be advanced through the application of validated imaging-based nomograms?Imaging-Based Nomograms in Clinical Oncology
Imaging-based nomograms are tools that are widely used to determine prognosis in clinical medicine, offering the ability to generate numerical probabilities of medical events at the individual level by integrating a wide range of variables such as data from magnetic resonance imaging (MRI), computed tomography (CT) os positron emission tomography (PET). A key application of imaging-based nomograms in the medical field is their application as integrated biological and clinical models to drive personalized oncology. Recent advances in the field of computational resources has enabled the smooth amalgamation of imaging-based nomograms into clinical decision making, which has led to the appearance of an abundance of imaging-based nomograms in oncology journals.
This Research Topic invites manuscripts exploring the validation and introduction of imaging-based nomograms in precision oncology, including:
- Validation and testing of imaging-based nomograms for cancer screening and detection
- The integration of validated imaging-based nomograms into clinical practice
- Validation of computational AI models in for imaging-based nomograms in oncology
We welcome submissions of several article types including but not limited to: Original Research, Reviews, Hypothesis and Theory, and Data Reports.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Other collections in our Editor's Challenge series:
Editor's Challenge: Claudio Cerchione - Is it Time for a Targeted Therapy in Multiple Myeloma? Editor's Challenge: Mohamed Rahouma - How Can We Optimize the Management and Treatment of Cardiac Tumors and Cardiac Complications of Cancer? Editor's Challenge: Dr. Luciano Mutti - What Is the True Impact of ICIs on Survival in the Treatment of Thoracic Malignancies? Editor's Challenge: Walter Storkus - Sexual Dimorphism and the Host Immune Response to Renal Cell Carcinoma Editor's Challenge: Dr. Qingxin Mu - How can Nanomedicine Approaches Advance Multi-targeting Strategy in Combination Cancer Therapy?